prothymosin alpha comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual description varies by batch |
| Solubility | Freely soluble in water | Aqueous buffers are commonly used |
| Typical storage temperature | -20 °C or below for powder | Reconstituted liquid kept at 2-8 °C short term |
| Purity method | Reversed-phase HPLC | Value derived from peak area integration |
| Identity method | Mass spectrometry | Confirms mass and sequence integrity |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
== Metabolism == Gliclazide undergoes extensive metabolism to several inactive metabolites in human beings, mainly methylhydroxygliclazide and carboxygliclazide. CYP2C9 is involved in the formation of hydroxygliclazide in human liver microsomes and in a panel of recombinant human P450s in vitro. But the pharmacokinetics of gliclazide MR are affected mainly by CYP2C19 genetic polymorphism instead of CYP2C9 genetic polymorphism.
On 7 August 2013, President Saakashvili said in an interview with Rustavi 2 TV that "the worst time for Georgia to engage in [military actions] was summer of 2008 and Russians knew it very well." Saakashvili said he offered Vladimir Putin in February 2008 to give up Georgia's NATO aspirations in exchange for Russia's help in restoring Georgia's control over the breakaway territories and that Georgia would endorse Russia's regional interests, but Putin refused by saying, "We do not exchange your territories for your geopolitical orientation." Saakashvili said that when he complained to Putin about escalation in the South Ossetian conflict zone, Putin threatened that the situation would even further deteriorate. Saakashvili said that Condoleezza Rice was assuring him in 2008 that there would be no war while Frank-Walter Steinmeier, German foreign minister, was the first to warn him about impending Russian attack. Saakashvili commented about the end of war in August 2008, "Eventually it was diplomacy and the U.S. sixth fleet that stopped Russia;" In March 2014, former president of Georgia, Mikheil Saakashvili wrote in The Washington Post, "Almost every Western politician to whom my government raised concerns in [July 2008] said that Russia would not attack and urged us to keep calm and not react to Russian moves." Saakashvili published an article in The Guardian where he wrote that "if the west had reacted properly to Georgia, Ukraine would never have happened." The Tagliavini Commission and actions of the EU emboldened Putin to act against Ukraine.
Current good manufacturing practices (cGMP) are those conforming to the guidelines recommended by relevant agencies. Those agencies control the authorization and licensing of the manufacture and sale of food and beverages, cosmetics, pharmaceutical products, dietary supplements, and medical devices. These guidelines provide minimum requirements that a manufacturer must meet to assure that their products are consistently high in quality, from batch to batch, for their intended use. The rules that govern each industry may differ significantly; however, the main purpose of GMP is always to prevent harm from occurring to the end user. Additional tenets include ensuring the end product is free from contamination, that it is consistent in its manufacture, that its manufacture has been well documented, that personnel are well trained, and that the product has been checked for quality more than just at the end phase. GMP is typically ensured through the effective use of a quality management system (QMS). Good manufacturing practice, along with good agricultural practice, good laboratory practice and good clinical practice, are overseen by regulatory agencies in the United Kingdom, United States, Canada, various European countries, China, India and other countries.
== Available forms == The abuse-deterring effects of atropine when used as an adulterant are reasonably effective in reducing the combination's potential for recreational use. It combines the mechanisms of naloxone and paracetamol (the two more commonly used abuse-deterring agents) by increasing the likelihood of the overdose resulting in harmful and/or fatal sequelae (as does paracetamol), in addition to reliably producing unpleasant side-effects which "spoil" the opioid euphoria and discourage abusers from overdosing again following their initial experience (as does naloxone). This does not deter the use of single doses of difenoxin to potentiate another opiate, the anticholingeric activity of a single tablet is actually likely to increase the pleasurable effects of opioid use in a manner similar to combining one or more opioids with orphenadrine.
The same month, Lineage entered the Spanish marketplace, acquiring cold storage firm Frigorificos de Navarra of Gijón, Spain from Frioastur and, in June 2021, entered the European freight industry with its acquisition of Rotterdam-based UTI Forwarding, and also acquired Kloosterboer Group in Europe, and the cold storage division of Claus Sorensen Group in Denmark. In November 2021, Lineage expanded into the Italian cold storage market with the acquisition of Kantaro SRL. In January 2022, Lineage continued its expansion by acquiring Auscold Logistics in South Australia. In the same month, Lineage also acquired Van Tuyl Logistics, as well as individual locations from H&S Coldstores in Beneden-Leeuwen and Frigocare Rotterdam BV in Rotterdam. In March, Lineage further expanded its network by acquiring MTC Logistics, adding nearly 38 million cubic feet of capacity and more than 113,000 pallet positions in the United States and its presence at key ports along the U.S. East and Gulf Coasts. In April, Lineage acquired VersaCold Logistics to expand its presence in Canada. Later in May, the company acquired Mandai Link Logistics to expand into Singapore. In August, Lineage acquired Cold Storage Nelson in New Zealand. This increased its presence in the Asia-Pacific area. In August 2023, Lineage expanded its European network by acquiring Grupo Fuentes, a Spanish transport and cold store operator. In addition, Lineage strengthened its presence in northern Vietnam through a joint venture with SK Logistics.
Sources: en.wikipedia.org
=== Infrared ear thermometers === Diatek Corporation and NASA developed an aural thermometer that measures the thermal radiation emitted by the eardrum, similar to the way the temperature of stars and planets are measured. This method avoids contact with mucous membranes and permits rapid temperature measurement of newborn or incapacitated patients. NASA supported the Diatek Corporation through the Technology Affiliates Program.
with equality in the equilateral case. More strongly, Barrow's inequality states that if the interior bisectors of the angles at interior point P (namely, of ∠APB, ∠BPC, and ∠CPA) intersect the triangle's sides at U, V, and W, then
She befriends investor Jesse Bloom and secures him as a client by helping him seize control of healthcare startup Rican, undercutting Felim and contributing to Eric’s removal from the trading floor. Harper begins a relationship with new MD Daniel Van Deventer (DVD) and travels to Berlin to confront her estranged brother, who rebuffs her. When Pierpoint plans to fold London into New York, Harper engineers a survival bid with Eric to preserve a London office, getting DVD fired. After Jesse manipulates her into committing insider trading, Eric shields her by exposing her forged transcripts instead, getting her fired. In series 3, six weeks prior to the main events, Harper accompanies Yasmin on a cruise in Mallorca and helps cover up Charles Hanani’s drowning. In the present, Harper works at ethical fund FutureDawn, where she earns Petra Koenig’s trust during the tumultuous Lumi IPO by helping hedge her exposure; the two co-found their own firm, LeviathanAlpha, with backing from Otto Mostyn. Harper enlists Pierpoint as their broker to humiliate Eric and illegally plans a short of Pierpoint’s ESG-backed debt, using an unwitting Yasmin to obtain information. The betrayal damages their friendship. Harper ultimately abandons the short but partners with Otto months later to launch a new hedge fund focused on shorting corrupt firms they can control. She and Yasmin also reconcile. In series 4, Harper runs a short-only fund within Otto's asset management firm but grows frustrated with his tight oversight, later learning it is tied to his political interests.
Polycarbonates contain Bisphenol A. Since 2008, at least 40 countries have banned the use of plastics containing Bisphenol A in baby bottles due to safety concerns (see Regulation). Bottles made of polycarbonate may be marked as "#7 PC". Bisphenol S (BPS) and Bisphenol F (BPF) have been used as substitutes for BPA. They are structurally similar. Comparisons of BPA, BPS and BPF have found that these chemicals have similar potency and action to BPA and may pose similar dangers in terms of endocrine-disrupting effects. This has led to criticisms of the chemical industry and for calls to deal with bisphenols in groups, not individually. In 2021, the Canadian government agencies Environment and Climate Change Canada (ECCC) and Health Canada (HC) held consultations with the goal of grouping 343 known BPA analogs and functional alternatives. Polyethersulfone plastic (PES) does not contain BPA but does include Bisphenol S (BPS). An assessment of a variety of different baby bottles in use in 2016, reported 4 bottles to be of "high concern", 14 bottles to be of "concern"; and only 6 bottles to be of "no concern" These of "no concern" included two polyamide (PA) and two polyethersulfone (PES) bottles, a stainless steel bottle, and one of the 17 polypropylene (PP) bottles tested. Phthalates, found in polyvinyl chloride (PVC), are another area of concern. Referred to as "everywhere chemicals" because they are so common, phthalates make plastic more flexible, and have been used in pacifiers and nipples or teats for bottles.
Sources: en.wikipedia.org
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.
Mass spectrometry is the standard confirmation of molecular mass and acetylation state. Chromatography establishes purity but does not identify the molecule on its own. The two techniques are normally applied together during verification.
No, because the reported value reflects the detection method and wavelength used, which vary between laboratories. A number stated without method details cannot be compared directly with another supplier's figure. Requesting the chromatogram and the method conditions is a common way to interpret it.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.